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Nestin-Cremice have a significantmetabolic phenotype that is hard to discern from current literature. Indeed,
the Cre-lox system has numerous problems that can affect physiological parameters, and these are missed
when the correct control strains are not used. Despite the increasing use of the Cre-lox system, these issues
were not visible to the scientific community previously and may have affected published work. This makes it
important to highlight the issues and raise awareness of the pitfalls of the Cre-lox system. Therefore, this
perspective will discuss the impact of CNS and peripheral ‘‘off-target’’ Cre recombination on metabolic sys-
tems and describe the development of new approaches to obviate the difficulties.Introduction
Over the past three decades, genetic engineering in mice has
become an essential tool in biomedical research, from early
manipulations, wherein germline targeting allowed the genera-
tion of whole-animal knockout or transgenic expression (Costan-
tini and Lacy, 1981; Gordon et al., 1980; Thompson et al., 1989),
to subsequent studies using Cre-lox technology, which have
enabled cell-type-specific modifications to be made. As is often
the case with any new technological advance, these refinements
overcame some of the inflexibility of conventional overexpres-
sion and knockout models, but pitfalls in the Cre-lox system
have emerged. Although in the past there have been numerous
reports stating the need for assessment of the independent
effects of Cre-driven transgenes on experimental outcomes
(Forni et al., 2006; Lee et al., 2006), a wealth of literature con-
tinues to be generated in which these controls are omitted. Our
own experience in conducting CNS-specific manipulations
elucidated a marked metabolic phenotype in mice carrying the
Nestin-Cre transgene. In addition to knocking out genes, Cre-
lox recombination can be used to insert genes. Knockin mice
with targeted gene expression or gene mutations were originally
thought to be more accurate than transgenic models. However,
because these use a Cre-lox system, they have many of the
same problems as tissue-specific knockoutmice do. The current
perspective aims to highlight some of the issues that need to be
addressed when using Cre-lox technology to target CNS path-
ways in order to determine ‘‘real’’ effects from artifacts.
The Basics and Issues of Cre-lox Technology
The Cre-lox system, discovered in bacteriophage P1 (Sternberg
and Hamilton, 1981), uses the enzyme Cre recombinase to
drive recombination of DNA between two loxP sites (Figure 1).
Through exploitation of this simple system, mouse models
have been generated in which a critical region of a gene or
regulatory genomic segment is flanked with loxP sites (‘‘floxed’’
targets). Crossing these floxed mice with a strain in which a tis-
sue-specific promoter drives Cre results in recombination within
defined cell types and the generation of tissue-specific knock-
outs (Figure 1).One of the problems with this approach is that pronuclear
microinjection, which is the most common method for genera-
tion of a Cre-expressing mouse, does not control for the site of
Cre-recombinase integration into the genome (Cartwright and
Wang, 2009; Lee et al., 2006). As a result, Cre integration is
random and can lead to multiple copies on single-chromosomal
loci, as well as potentially disrupting endogenous gene expres-
sion. Furthermore, it can lead to unwanted or very low levels of
Cre activity (Cartwright and Wang, 2009). Nonuniformity in Cre
activity can lead to a mosaic pattern of recombination (Ryding
et al., 2001) and inefficient deletion of the gene by Cre (Branda
and Dymecki, 2004; Gannon et al., 2000; Shao et al., 2002).
The fidelity of the system is critically dependent on the true
specificity of the chosen promoter in terms of its expression pro-
file, not only during adult life, but also during development.
Increasingly, genes thought to have a restricted tissue-specific
expression have subsequently been shown to drive recombina-
tion in unexpected sites (discussed in more detail in the section
after next). This is most often due to legitimate Cre expression,
wherein a promoter is expressed in early embryonic life in multi-
ple cell types, leading to deletion of the gene of interest in addi-
tional tissues (Matthaei, 2007). However, it can also arise due to
unexpected promoter expression in adulthood. In addition,
some Cre strains have been shown to express ectopic Cre
recombinase in the testes, leading to excision events in the
germline and, as a result, recombination of the targeted allele
in all tissues of the offspring (Rempe et al., 2006). In this case,
specific breeding strategies can be used in order to avoid the
testicular Cre expression, utilizing female Cre carriers crossed
with floxed males.
In order to eradicate false results due to aberrant tissue
expression, screening for gene recombination, rather than for
the presence or absence of Cre, should be carried out. Patterns
of nonspecific or ineffective deletion can be visualized by
crossing Cre strains with reporter mice, such as the ROSA-
LacZ mouse. These animals possess a loxP flanked DNA
segment that prevents lacZ gene expression. Thus, when
crossed with Cre animals, lacZ reporter gene expression is
driven irreversibly in cells in which Cre is expressed and isCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 21
Figure 1. Generation of Tissue-Specific
Knockouts Using Promoter Cre-loxP
Recombination
Mice expressing Cre recombinase (Cre) under the
control of a tissue-specific promoter are mated
with mice in which the gene of interest is flanked
by loxP sites (‘‘floxed’’ mice). In the offspring,
recombination of floxed genes occurs only in cells
in which Cre is expressed, leading to ‘‘tissue-
specific’’ targeting.
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strain has its limitations, because as a complex allele it can
be difficult to excise, often leading to underreporting of Cre
expression (Xu et al., 2010; Xu et al., 2008). Other ROSA alleles
being used now incorporate additional promoter sequences,
such as CAG, which yield much higher levels of Cre expression
(Madisen et al., 2010). More recently, in vivo visualization of
Cre expression has been made possible using strains such as
the pink mouse, which uses a Tomato reporter line for visualiza-
tion (Hartwich et al., 2012). However, the different reporter lines
can lead to different expression patters (Hartwich et al., 2012),
and generally only one strain is used for examining the expres-
sion patterns. Overall, though, these strains allow investigators
to effectively map sites at which Cre recombinase has been
expressed, and hence assess the integrity of intended tissue-
specific modifications.
Furthermore, there are also some difficulties associated with
loxP sites. Although the 34 bp loxP consensus sequence is
not predicted in the mammalian genome, many pseudo-loxP
sites have been identified (Thyagarajan et al., 2000). These are22 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.sequences that, although not identical
to those in the P1 bacteriophage, retain
sufficient identity to allow Cre-recombi-
nase binding and subsequent recombi-
nation at unintentional sites.
Another important factor influencing
the efficiency of gene deletion is the
background strain of the mice used. In
general, strain-129-derived embryonic
stem cells are used for gene-manipula-
tion studies because of the efficacy
of germline transfer compared to other
strains. However, these mice do not
breed well and have abnormal behavioral
responses and congenital hypoplasia of
the corpus callosum (Crawley et al.,
1997; Mishina and Sakimura, 2007;
Wahlsten, 1982), making them largely
unsuitable for CNS knockout studies.
Given these limitations, founder lines are
generally backcrossed onto a suitable
strain background (such as C57BL/6),
mitigating most of these concerns.
Additional Effects of Cre
Recombinase Itself
In addition to targeting removal in unin-
tended tissues, genomic insertion of Crerecombinase in itself can markedly affect physiological function.
These effects of Cre recombinase have been well documented
for over a decade, when it was found that Cre can catalyze
illegitimate recombination, leading to overt pathological conse-
quences in the offspring (Schmidt et al., 2000). Furthermore,
Cre expression has been associated with reduced proliferation
(Loonstra et al., 2001; Pfeifer et al., 2001) and increased
apoptosis (Naiche and Papaioannou, 2007; Pfeifer et al., 2001)
in cell lines. In vivo, this has been shown specifically in the brain,
where damage to brain cells and microcephaly are potential
consequences (Forni et al., 2006; Pfeifer et al., 2001; Qiu et al.,
2011). It is therefore perhaps surprising that Cre-recombinase
mice are not routinely used as control mice in Cre-lox studies.
Indeed, publications have stated for many years that Cre
controls need to be included for a full interpretation of the data
in tissue-specific knockout studies (Forni et al., 2006; Loonstra
et al., 2001; Naiche and Papaioannou, 2007). Even though this
information has been available since an early stage in this field
of research, correct controls are still not always used (discussed
in the next section).
Figure 2. Nonspecific Expression of Cre Recombinases
Many Cre-recombinase strains used in metabolic studies have secondary effects in other unrelated tissues. (Information taken from http://cre.jax.org/data.html;
Delacour et al., 2004; Dubois et al., 2006; Honig et al., 2010; Lee et al., 2013; Martens et al., 2010; Mazur et al., 2010; Mullican et al., 2013; Padilla et al., 2012;
Rempe et al., 2006; Schonhoff et al., 2004; Song et al., 2010; Street et al., 2005; Zhang et al., 2012.)
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Since its development (Tronche et al., 1999), Nestin-Cre has
been the predominant promoter construct used for gene deletion
in neuronal tissues. Nestin is an intermediate filament protein,
highly expressed in neuronal progenitor cells, and thus has
been used for driving deletions specifically in the CNS and
peripheral nervous system (PNS). Recombination occurs from
embryonic day 11 (when Nestin-Cre expression is first
observed), though is not complete until postnatal life (Liang
et al., 2012). Nestin-Cre lines are commercially available from
The Jackson Laboratory and therefore have been widely utilized.
However, it is increasingly recognized that the strain itself has
some background effects, in terms of nonspecific gene deletion
as well as a metabolic phenotype (addressed in the next para-
graph), making it difficult to interpret study results from these
mice. This nonspecificity of the Nestin-Cre transgene is not a
recent concern and has been well documented, with expression
of Nestin-Cre also localized to the kidney and somite-derived tis-
sues such as muscle and dermis (Dubois et al., 2006), as well as
the pancreas (Delacour et al., 2004). More worryingly, the web-
site for The Jackson Laboratory now shows nonspecific expres-
sion of Nestin-Cre in many other tissues (Figure 2; http://cre.jax.
org/Nes/Nes-CreNano.html).
In recent studies wherein we deleted the glucocorticoid-
regenerating enzyme 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1) from the CNS, we found that the Nestin-Cre
strain (The Jackson Laboratory no. 003771) also had ametabolic
phenotype, masking any potential effect of the 11b-HSD1 dele-
tion itself. The phenotype of this Nestin-Cre strain has been
published previously but was not available at the outset of our
experiments. However it is not readily apparent in the literature
even now, because the information on the metabolic phenotype
is in the supplemental material and not referred to in the title orabstract (Briancon et al., 2010). The earliest Nestin-Cre study,
knocking out the glucocorticoid receptor in the CNS, demon-
strated reduced body length, decreased body weight, and
altered fat distribution in Grl1 mice compared to Grl1loxP/loxP
controls (Tronche et al., 1999). These observations mirror those
that we have recently found and could potentially be attributed
solely to the presence of the Nestin-Cre transgene (Figure 3).
Given that Nestin-Cremicewere not used as controls in the initial
study, it is possible, in fact, that the presence of the Nestin-Cre
transgene, rather than the absence of the CNS glucocorticoid
receptor, is driving this phenotype.
The marked body weight and length phenotype of Nestin-Cre
mice is most likely a consequence of significantly lower growth
hormone (GH) levels in these animals (Galichet et al., 2010). In
addition to effects on growth per se, lower levels of GH can
improve insulin sensitivity, given that increased circulating GH
leads to impaired insulin action (Takano et al., 2001; Yakar
et al., 2004). Thus, the relative GH deficiency in the Nestin-Cre
mice may be implicit in the improved insulin sensitivity observed
in this strain (Figure 3; Briancon et al., 2010). Equally, the Nestin-
Cre expression in the pancreas may also influence the insulin
sensitivity (Delacour et al., 2004). Curiously, although these
Nestin-Cre strains show increased insulin sensitivity after
high-fat feeding, they show no improvement in glucose levels
(Briancon et al., 2010).
The influence of the Nestin-Cre background has not been
considered in many publications. Many of these studies, even
very recent ones (Kocalis et al., 2012; Price et al., 2013), do not
use Nestin-Cre mice as controls, instead using floxed animals
or pure wild-type mice of the same strain background (e.g.,
C57Bl/6). Some studies have not given details of the strains
they have used for comparison (Gao et al., 2004). The metabolic
changes in the Nestin-Cre strain are only likely to be problematicCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 23
Figure 3. Mice Carrying the Nestin-Cre
Transgene Exhibit a Marked Metabolic
Phenotype
Although the mechanisms underlying the pheno-
type of Nestin-Cre mice are complex, the
nonspecific recombination, which leads to hypo-
pituitarism and reduced growth-hormone levels,
probably contributes. In our experiments,
compared with C57Bl/6J control mice, Nestin-Cre
animals exhibited a significant reduction in body
length and lower lean mass, as well as an
improved insulin sensitivity (determined using the
homeostatic model of assessment—insulin
resistance [HOMA-IR]). Data is expressed as the
mean ± SEM; **p < 0.01, ***p < 0.001; n = 10–14.)
(Mice were bred at AstraZeneca, Alderley Park,
UK. All work was carried out in accordance with
the UK Home Office Animals [Scientific Pro-
cedures] Act 1986 and approved by the local
ethical review committee). Potentially, each of
these effects could be attributed to the reduced
growth-hormone levels observed in Nestin-Cre
mice (Galichet et al., 2010).
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metabolic phenotype. This could potentially be the case for
PPARd knockdown, as it is not clear whether the increased
body-fatmass seen in this studywas due to theNestin-Creback-
ground or the changes in PPARd (Kocalis et al., 2012). A caveat to
the reported metabolic phenotype is the different strains of
Nestin-Cre mice that are available, not all of which have been
shown to have a body-weight or metabolic phenotype (Bence
et al., 2006, 2010). However, given the variability between
strains, care must be taken when interpreting data from all
Nestin-Cre studies. Based on the evidence available, it would
be advisable to include Nestin-Cre controls in all experimental
designs to prevent misinterpretation of the findings (Figure 4).
Nonspecific CNS Cre Effects Are Not Limited
to Nestin-Cre
An alternative CNS-‘‘specific’’ promoter is Synapsin-Cre, which
utilizes the rat Synapsin I promoter to drive neuron-specific
Cre-recombinase activity. Although initial studies reported
gene expression restricted almost entirely to the CNS (Hoesche24 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.et al., 1993), subsequent findings showed
significant expression of the transgene in
other tissues, notably testes (Rempe
et al., 2006; Street et al., 2005). Conse-
quently, when male Synapsin-Cre mice
were mated with floxed females, marked
germline recombination occurred (des-
cribed above; Rempe et al., 2006) with
obvious consequences for the derived
progeny, which no longer exhibited
tissue-specific deletion. Clearly, investi-
gators need to be aware of these issues
when considering mating strategies.
In addition to modifying gene expres-
sion within the entire CNS, the generation
of cell-type-specific modifications is
increasingly used. As an example, thepro-opiomelanocortin (POMC) neurons, critical in the regulation
of energy balance, have been targeted by several groups. How-
ever, recent elegant studies have utilized transgenic tools for
studying the distribution of POMC neurons during development
and have identified not only that POMC is relatively widely ex-
pressed in the developing brain (Padilla et al., 2012), but that a
proportion of cells that express POMCduring development actu-
ally differentiate into neuropeptide Y (NPY) neurons (Padilla et al.,
2010). Given that NPY has actions antagonistic to POMC, these
findings may have implications for studies in which POMC-
driven manipulations have been made. Furthermore, it is difficult
to determine the extent to which off-target recombination con-
tributes to the reported phenotypes (highlighted by Padilla
et al., 2012).
Although there is no pan-neuronal Cre line without significant
drawbacks, the number of lines available is rapidly increasing.
Combined with technological advances in controlling the activity
of Cre recombinase (addressed in the section after next), these
approaches will probably improve neuronal gene targeting in
the future.
Figure 4. Recommended Future Requirements of the Cre-lox Strategy for Publication
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Studies designed to investigate the effects of gene deletion in a
peripheral tissue have also been hampered by off-target effects,
often with unintended modification at CNS sites (Figure 2). Given
that the brain plays a key role in the regulation of peripheral-tissue
function, it canbecomeextremelydifficult todetermine the relative
contribution of intended peripheral versus off-target CNS effects.
An accompanying perspective by Magnuson and Osipovich
(2013) highlights that the ability to generate mice with
pancreas-specific deletions is confounded by genes having
significant expression within other tissues, notably the CNS
and specifically the hypothalamus (Gannon et al., 2000; Song
et al., 2010). Cre expression driven by supposedly pancreas-
specific genes—the rat insulin promoter (RIP-Cre), neurogenin-3
promoter (Ngn3-Cre), and pancreas-duodenum homeobox 1
promoter (Pdx1-Cre)—have all been found to result in significant
recombination within various hypothalamic nuclei (Song et al.,
2010). It is therefore not possible at present to determine the
contribution of pancreatic versus CNS effects on the observed
glucose-tolerance phenotypes seen in these models.
Similarly, attempts to define the metabolic effects of adipose-
specific gene removal using the aP2/FABP4-Cre mouse lines
have been thwarted by studies identifying significant recombina-
tion in numerous other tissues, including both the PNS and CNS
(Martens et al., 2010; Mullican et al., 2013; Zhang et al., 2012), as
well as a relatively poor recombination efficiency (Halberg et al.,
2009). A recent study (Lee et al., 2013) has systematically deter-
mined the relative efficiency and specificity of several Cre lines
that are widely used in the literature for modifying adipose
gene expression. Their findings showed that in addition to vari-
ability in recombination efficiency among the different Cre lines
used, the floxed line counterpart was a major determinant of
efficacy. This emphasizes the need for caution when planning
and interpreting experimental data.
Overcoming the Problems: Technological Advances
in Gene Targeting
Although there are many potential pitfalls to the Cre-lox
system in its present form, technological advances continueto provide increasingly elegant techniques for manipulating
cellular function in a discrete spatiotemporal manner. These
include the use of targeted viruses, inducible-Cre systems,
optogenetics, and DREADD (designer receptors exclusively
activated by designer drugs) technology to modify gene
expression.
Adeno-associated viruses (AAVs) are increasingly used for
targeting Cre expression to distinct locations within the brain.
Using this technology, Cre recombinase is inserted into the
4.7 kbp parvovirus genome, and the resultant AAV-Cre
construct is then injected directly into a region of interest,
driving recombination within a restricted site. Used in adult
animals, this approach negates the developmental effects asso-
ciated with many Cre strains and can afford deletion within
small nuclei such as the arcuate nucleus of the hypothalamus.
AAVs are highly efficient for gene delivery (Dayton et al.,
2012), show very little toxicity or immunogenic reaction (Ahmed
et al., 2004; Bessis et al., 2004), and typically delete the gene of
interest within 3–7 days post injection (Ahmed et al., 2004; Kas-
par et al., 2002). Some studies have shown activity for up to
6 months (Kaspar et al., 2002), allowing for long-term gene-
deletion studies to be carried out. However, the use of AAVs
has some technical limitations. The AAV vector itself has a small
cloning capacity, which can limit the size of the gene insertion.
Additionally, there are many different serotypes of AAVs, mak-
ing the choice of AAV vector for the correct tissue type and spe-
cies very important. The technique itself is difficult, requiring
very accurate intracerebroventricular injections and having a
high rate of unsuccessful gene deletions. However, the positive
effects of overcoming nonspecific gene deletion outweigh the
technical limitations.
An alternative approach is self-deleting Cre, whereby Cre is
integrated into the host genome, expressed, and then sub-
sequently deleted from the host cell (Pfeifer et al., 2001). This
minimizes toxic cellular effects, but again, the specificity of
this system will depend on the fidelity of Cre expression for
the period that it is functionally expressed. Precise control of
defined neurons upon exposure to light stimulus (reviewed in
detail in Rein and Deussing, 2012) can now be achieved. ThisCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 25
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optogenetic techniques, in which light-sensitive channels (excit-
atory channelrhodospin-2 or inhibitory halorhodopsin pump) are
targeted to specific neuronal populations. However, the inva-
siveness of light stimulation and potential inaccessibility of
scattered neuronal populations currently limits the use of this
approach.
Transgenes utilizing inducible Cre, wherein Cre recombinase
is nonfunctioning during development and its expression is
then controlled in an on/off manner (e.g., by administration of
tetracycline or tamoxifen), allows temporal control of recombi-
nase activity at the desired time point during development or in
adulthood. This method is useful in overcoming developmental
effects of Cre expression, as well as ectopic recombination
due to transient Cre expression. However, some studies have
shown that Cre is still expressed for many weeks after removal
of the on/off agent, potentially confounding the results of time-
sensitive studies (Reinert et al., 2012).
DREADD technology utilizes mutated muscarinic G protein-
coupled receptors, which lose their ability to bind natural
ligands but are activated by clozapine-N-oxide (CNO), an
otherwise inert drug (Alexander et al., 2009; Dong et al.,
2010). Administration of CNO is then used to activate the
targeted cells, which occurs within minutes of peripheral
injection (Alexander et al., 2009; Krashes et al., 2011). This
approach, although allowing controlled and noninvasive acti-
vation of cells, does not afford the temporal accuracy that is
achieved using optogenetic techniques, in that the ‘‘switching
off’’ will depend on the time taken for CNO to be removed
from the system. This technology, although recently developed,
has already been used in metabolic studies for elucidating the
effects of AgRP neurons in feeding behavior (Krashes et al.,
2011).
Each of these approaches comes with its own set of limita-
tions, but it is clear that future technological advances will
continue to refine these techniques.
General Conclusions
The use of Cre-based technology is still incredibly important to
our understanding of disease and body systems. However,
there needs to be a more widespread awareness of potential
caveats of this system in order to maximize the usefulness
and validity of results. At present, due to the difficulty in publish-
ing negative results, there is a lack of awareness of the prob-
lems associated with Cre background strains in the literature.
To overcome the problem with this technique and to prevent
this type of issue with emerging technologies, there needs to
be a shift in publication strategy to enable these findings to be
overtly disseminated. This does not necessarily need to take
the form of a full publication, but perhaps a novel online forum
could provide avenues for discussion of these technology
issues in an approach similar to a ‘‘news and views’’ section
in a journal.
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